Williams, John G <br/><br/>
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.  [electronic resource] 

 -  The lancet. Gastroenterology & hepatology  09 2016 
 - 15-24 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Pragmatic Clinical Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2468-1253 
<br/><br/><label>Standard No.: </label>10.1016/S2468-1253(16)30003-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Area Under Curve<br/>Colitis, Ulcerative--drug therapy<br/>Cost-Benefit Analysis<br/>Cyclosporine--economics<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Hydrocortisone--therapeutic use<br/>Immunosuppressive Agents--economics<br/>Infliximab--economics<br/>Infusions, Intravenous<br/>Male<br/>Middle Aged<br/>Severity of Illness Index<br/>Treatment Outcome<br/>United Kingdom<br/>Young Adult